These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 25998434)
21. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. O'Connor R; Baines SD; Freeman J; Wilcox MH J Antimicrob Chemother; 2008 Oct; 62(4):762-5. PubMed ID: 18606787 [TBL] [Abstract][Full Text] [Related]
22. Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks. López-Ureña D; Quesada-Gómez C; Montoya-Ramírez M; del Mar Gamboa-Coronado M; Somogyi T; Rodríguez C; Rodríguez-Cavallini E Emerg Microbes Infect; 2016 May; 5(5):e42. PubMed ID: 27165560 [TBL] [Abstract][Full Text] [Related]
24. Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait. Jamal WY; Rotimi VO PLoS One; 2016; 11(8):e0161411. PubMed ID: 27536994 [TBL] [Abstract][Full Text] [Related]
25. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes. Huang H; Wu S; Wang M; Zhang Y; Fang H; Palmgren AC; Weintraub A; Nord CE Int J Antimicrob Agents; 2009 Apr; 33(4):339-42. PubMed ID: 19097757 [TBL] [Abstract][Full Text] [Related]
26. Molecular characterization and antimicrobial susceptibilities of Clostridium difficile clinical isolates from Victoria, Australia. Mackin KE; Elliott B; Kotsanas D; Howden BP; Carter GP; Korman TM; Riley TV; Rood JI; Jenkin GA; Lyras D Anaerobe; 2015 Aug; 34():80-3. PubMed ID: 25944720 [TBL] [Abstract][Full Text] [Related]
27. Antibiotic profiling of Clostridium difficile ribotype 176--A multidrug resistant relative to C. difficile ribotype 027. Krutova M; Matejkova J; Tkadlec J; Nyc O Anaerobe; 2015 Dec; 36():88-90. PubMed ID: 26256807 [TBL] [Abstract][Full Text] [Related]
28. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Drudy D; Harnedy N; Fanning S; Hannan M; Kyne L Infect Control Hosp Epidemiol; 2007 Aug; 28(8):932-40. PubMed ID: 17620240 [TBL] [Abstract][Full Text] [Related]
29. [Survey of susceptibility of clinical Clostridium diffiicile strains isolated from patients hospitalised in different departments of paediatric hospital to antimicrobial agents]. Wultańska D; Obuch-Woszczatyński P; Pituch H; Luczak M Med Dosw Mikrobiol; 2007; 59(2):161-8. PubMed ID: 17929413 [TBL] [Abstract][Full Text] [Related]
30. [Antimicrobial susceptibility of Clostridium difficile clinical isolates collected from 2001 to 2007 in a French university hospital]. Cattoir V; Ould-Hocine ZF; Legrand P Pathol Biol (Paris); 2008; 56(7-8):407-11. PubMed ID: 18845403 [TBL] [Abstract][Full Text] [Related]
31. PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates. Solomon K; Fanning S; McDermott S; Murray S; Scott L; Martin A; Skally M; Burns K; Kuijper E; Fitzpatrick F; Fenelon L; Kyne L J Antimicrob Chemother; 2011 Sep; 66(9):1976-82. PubMed ID: 21712239 [TBL] [Abstract][Full Text] [Related]
32. Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. Freeman J; Stott J; Baines SD; Fawley WN; Wilcox MH J Antimicrob Chemother; 2005 Nov; 56(5):988-9. PubMed ID: 16195254 [No Abstract] [Full Text] [Related]
33. Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting. Venugopal AA; Riederer K; Patel SM; Szpunar S; Jahamy H; Valenti S; Shemes SP; Khatib R; Johnson LB Scand J Infect Dis; 2012 Apr; 44(4):243-9. PubMed ID: 22077148 [TBL] [Abstract][Full Text] [Related]
34. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Barbut F; Mastrantonio P; Delmée M; Brazier J; Kuijper E; Poxton I; Clin Microbiol Infect; 2007 Nov; 13(11):1048-57. PubMed ID: 17850341 [TBL] [Abstract][Full Text] [Related]
35. Faecal shedding of antimicrobial-resistant Clostridium difficile strains by dogs. Álvarez-Pérez S; Blanco JL; Peláez T; Lanzarot MP; Harmanus C; Kuijper E; García ME J Small Anim Pract; 2015 Mar; 56(3):190-5. PubMed ID: 25483272 [TBL] [Abstract][Full Text] [Related]
36. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Wong SS; Woo PC; Luk WK; Yuen KY Diagn Microbiol Infect Dis; 1999 May; 34(1):1-6. PubMed ID: 10342100 [TBL] [Abstract][Full Text] [Related]
37. Comparison of antimicrobial susceptibility among Clostridium difficile isolated from an integrated human and swine population in Texas. Norman KN; Scott HM; Harvey RB; Norby B; Hume ME Foodborne Pathog Dis; 2014 Apr; 11(4):257-64. PubMed ID: 24320797 [TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Huang H; Weintraub A; Fang H; Wu S; Zhang Y; Nord CE Anaerobe; 2010 Dec; 16(6):633-5. PubMed ID: 20849968 [TBL] [Abstract][Full Text] [Related]
39. Comparison of agar dilution and broth microdilution methods for Clostridium difficile antimicrobial susceptibility testing. Igawa G; Casey M; Sawabe E; Nukui Y; Okugawa S; Moriya K; Koike R; Tohda S; Saito R J Glob Antimicrob Resist; 2016 Dec; 7():43-45. PubMed ID: 27598055 [TBL] [Abstract][Full Text] [Related]
40. Comparison of Clostridium difficile isolates from individuals with recurrent and single episode of infection. Richardson C; Kim P; Lee C; Bersenas A; Weese JS Anaerobe; 2015 Jun; 33():105-8. PubMed ID: 25769665 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]